| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $163,620 | 4 | 100 |
| Kuo Minnie | Chief Operating Officer | 0 | $0 | 1 | $8,854 | $-8,854 |
| Cheung Lily | Chief Human Resource Officer | 0 | $0 | 1 | $9,644 | $-9,644 |
| Cummings Keith Lamont | Chief Financial Officer | 0 | $0 | 1 | $30,723 | $-30,723 |
| Coulie Bernard | President and CEO | 0 | $0 | 1 | $114,400 | $-114,400 |
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective …
Over the last 12 months, insiders at Pliant Therapeutics, Inc. have bought $0 and sold $163,620 worth of Pliant Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Pliant Therapeutics, Inc. have bought $0 and sold $5.4M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-01-20 | Sale | Coulie Bernard | President and CEO | 89,375 0.1454% | $1.28 | $114,400 | -9.38% | |
| 2026-01-20 | Sale | Cummings Keith Lamont | Chief Financial Officer | 24,002 0.0391% | $1.28 | $30,723 | -9.38% | |
| 2026-01-20 | Sale | Cheung Lily | Chief Human Resource Officer | 7,534 0.0123% | $1.28 | $9,644 | -9.38% | |
| 2026-01-20 | Sale | Kuo Minnie | Chief Operating Officer | 6,917 0.0113% | $1.28 | $8,854 | -9.38% | |
| 2025-01-22 | Sale | Ouimette Mike | General Counsel & Corp. Sec'y | 10,230 0.0167% | $10.99 | $112,462 | -86.26% | |
| 2025-01-17 | Sale | Coulie Bernard | President and CEO | 52,419 0.0866% | $11.20 | $587,150 | -86.57% | |
| 2025-01-17 | Sale | Cummings Keith Lamont | Chief Financial Officer | 20,148 0.0333% | $11.20 | $225,680 | -86.57% | |
| 2025-01-17 | Sale | Hull Hans | Chief Business Officer | 15,936 0.0263% | $11.20 | $178,501 | -86.57% | |
| 2025-01-17 | Sale | Lefebvre Eric | Chief Medical Officer | 18,478 0.0305% | $11.20 | $206,974 | -86.57% | |
| 2025-01-17 | Sale | Ouimette Mike | General Counsel & Corp. Sec'y | 13,270 0.0219% | $11.20 | $148,639 | -86.57% | |
| 2025-01-17 | Sale | Cheung Lily | Chief Human Resource Officer | 3,740 0.0062% | $11.20 | $41,892 | -86.57% | |
| 2024-07-10 | Sale | Coulie Bernard | President and CEO | 38,710 0.0701% | $11.56 | $447,488 | +2.03% | |
| 2024-07-10 | Sale | Cummings Keith Lamont | Chief Financial Officer | 10,911 0.0198% | $11.56 | $126,131 | +2.03% | |
| 2024-07-10 | Sale | Hull Hans | Chief Business Officer | 9,900 0.0179% | $11.56 | $114,444 | +2.03% | |
| 2024-07-10 | Sale | Lefebvre Eric | Chief Medical Officer | 12,319 0.0223% | $11.56 | $142,408 | +2.03% | |
| 2024-07-10 | Sale | Ouimette Mike | General Counsel & Corp. Sec'y | 7,656 0.0139% | $11.56 | $88,503 | +2.03% | |
| 2024-01-17 | Sale | Coulie Bernard | President and CEO | 25,721 0.0414% | $17.23 | $443,173 | -24.72% | |
| 2024-01-17 | Sale | Cummings Keith Lamont | Chief Financial Officer | 9,781 0.0157% | $17.23 | $168,527 | -24.72% | |
| 2024-01-17 | Sale | Hull Hans | Chief Business Officer | 9,786 0.0158% | $17.23 | $168,613 | -24.72% | |
| 2024-01-17 | Sale | Lefebvre Eric | Chief Medical Officer | 10,295 0.0166% | $17.23 | $177,383 | -24.72% |
| Increased Positions | 44 | +34.11% | 10M | +19.71% |
| Decreased Positions | 55 | -42.64% | 15M | -29.09% |
| New Positions | 14 | New | 4M | New |
| Sold Out Positions | 18 | Sold Out | 2M | Sold Out |
| Total Postitions | 118 | -8.53% | 47M | -9.38% |
| Tang Capital Management Llc | $7,504.00 | 9.84% | 6M | +3,446 | +0.06% | 2025-09-30 |
| Woodline Partners Lp | $5,631.00 | 7.39% | 4.5M | +2M | +91.81% | 2025-09-30 |
| Point72 Asset Management, L.P. | $5,423.00 | 7.11% | 4.34M | +4M | New | 2025-09-30 |
| Morgan Stanley | $4,384.00 | 5.75% | 3.51M | -246,325 | -6.56% | 2025-09-30 |
| Blue Owl Capital Holdings Lp | $3,711.00 | 4.87% | 2.97M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $3,470.00 | 4.55% | 2.78M | -226,410 | -7.54% | 2025-09-30 |
| Acadian Asset Management Llc | $2,962.00 | 3.88% | 2.37M | +739,129 | +45.33% | 2025-09-30 |
| Citadel Advisors Llc | $2,924.00 | 3.84% | 2.34M | -16,431 | -0.7% | 2025-09-30 |
| Jpmorgan Chase & Co | $2,663.00 | 3.49% | 2.13M | +172,056 | +8.79% | 2025-09-30 |
| Redmile Group, Llc | $1,990.00 | 2.61% | 1.59M | -40,882 | -2.5% | 2025-09-30 |